By Healthcare Edge Editorial Staff
Eterna Therapeutics Inc. (Nasdaq: ERNA) said it appointed Sanjeev Luther as incoming President and Chief Executive Officer from Jan. 1, 2024.
Mr. Luther emphasized his commitment to advancing the reach and promise of mRNA cell engineering, underscoring the importance of innovation in shaping the future of transformative medicines, the company said in a statement.
“We are excited to have Sanjeev take on the role of President and CEO of Eterna as we continue our work to support the development of next-generation therapies using mRNA cell engineering,” said James Bristol, Ph.D., Chairman of Eterna’s Board of Directors.
Contact:
Editor@Executives-edge.com
